Arch Therapeutics Inc (ARTH) financial statements (2020 and earlier)

Company profile

Business Address 235 WALNUT STREET, SUITE 6
FRAMINGHAM, MA 01702
State of Incorp. NV
Fiscal Year End September 30
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,0232,1803,1821,9563,3784,6676,489
Cash and cash equivalents3,0232,1803,1821,9563,3784,6676,489
Inventory, net of allowances, customer advances and progress billings200347     
Inventory200347     
Prepaid expense     15288
Other undisclosed current assets330363595453240  
Total current assets:3,5532,8903,7762,4093,6184,8196,577
Noncurrent Assets
Property, plant and equipment1091114151719
Other noncurrent assets4444444
Total noncurrent assets:13131417192123
TOTAL ASSETS:3,5662,9023,7912,4273,6374,8406,599
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities402534129176131161183
Accounts payable402534129176131161183
Other undisclosed current liabilities230180142105146127176
Total current liabilities:631714270281277288359
Noncurrent Liabilities
Liabilities, other than long-term debt3,0362,9963,6922,3474,0243,1923,990
Derivative instruments and hedges, liabilities3,0362,9963,6922,3474,0243,1923,990
Total noncurrent liabilities:3,0362,9963,6922,3474,0243,1923,990
Total liabilities:3,6673,7103,9622,6274,3013,4804,349
Stockholders' equity
Stockholders' equity attributable to parent, including:(101)(807)(172)(201)(664)1,3602,251
Common stock187173173164162160151
Additional paid in capital40,23737,88537,69336,38336,09135,51732,845
Accumulated deficit(40,525)(38,865)(38,037)(36,748)(36,918)(34,317)(32,882)
Other undisclosed stockholders' equity attributable to parent      2,138
Total stockholders' equity:(101)(807)(172)(201)(664)1,3602,251
TOTAL LIABILITIES AND EQUITY:3,5662,9023,7912,4273,6374,8406,599

Income statement (P&L) ($ in thousands)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
Operating expenses(1,620)(1,524)(1,572)(1,507)(1,768)(2,233)(1,620)
Operating loss:(1,620)(1,524)(1,572)(1,507)(1,768)(2,233)(1,620)
Net loss:(1,620)(1,524)(1,572)(1,507)(1,768)(2,233)(1,620)
Other undisclosed net income (loss) attributable to parent(40)6962831,677(832)798(593)
Net income (loss) available to common stockholders, diluted:(1,660)(828)(1,289)170(2,600)(1,435)(2,213)

Comprehensive Income ($ in thousands)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
Net loss:(1,620)(1,524)(1,572)(1,507)(1,768)(2,233)(1,620)
Comprehensive loss, net of tax, attributable to parent:(1,620)(1,524)(1,572)(1,507)(1,768)(2,233)(1,620)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: